Pioneering diagnostics

bioMérieux Italia | Pioneering diagnostics

ULTIME NOTIZIE

16.07.2020

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products
15.07.2020

Second-Quarter 2020 Business Performance Preannouncement
15.07.2020

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
27.05.2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®
04.05.2020

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

NOTIZIE

COVID-19 Update

bioMérieux is actively committed in the fight against the new coronavirus

Creiamo valore per i nostri clienti

Scopri attraverso I video, il valore dei clienti per bioMérieux

BIOMERIEUX LISTINO 2020

LISTINO BIOMERIEUX ITALIA 2020

Catalogo Formazioni

CATALOGO CORSI DI FORMAZIONE SCIENTIFICI, TECNICI E MANAGERIALI 2019/2020

Terreni Chromid

TERRENI CROMOGENI

FilmArray

APPROFONDIMENTI

bioMérieux Corporate | bioMérieux Industry | bioMérieux Diagnostics

bioMérieux Italia Spa | Sede Legale Via di Campigliano, 58 Loc.Ponte a Ema

50012 Bagno a Ripoli (FI) Italia | Capitale Sociale € 9.000.000 i.v. Socio Unico

n.REA FI 443558 | C.F. 07146020586 | P.IVA 01696821006